Developmental pharmacokinetics

Seminars in Pediatric Neurology

Volumn 17, Issue 4, 2010, Pages 208-213

  Anderson, Gail D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ESLICARBAZEPINE ACETATE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FEXOFENADINE; GABAPENTIN; GLUCURONOSYLTRANSFERASE; HARKOSERIDE; LAMOTRIGINE; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

AGE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG MILK LEVEL; DRUG PROTEIN BINDING; KIDNEY METABOLISM; LIVER METABOLISM; PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW; URINARY EXCRETION;

ABSORPTION; AGE FACTORS; HUMANS; KIDNEY; LIVER; MILK, HUMAN; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEIN BINDING;

EID: 78650267242     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spen.2010.10.002     Document Type: Review

References (42)

1. Kearns G.L., Abdel-Rahman S.M., Alander S.W., et al. Developmental pharmacology-Drug disposition, action, and therapy in infants and children. N Engl J Med 2003, 349:1157-1167.
2. Anderson G.D., Lynn A.M. Optimizing pediatric dosing: A developmental pharmacologic approach. Pharmacotherapy 2009, 29:680-690.
3. Al Za'abi M., Lanner A., Xiaonian X., et al. Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. Ther Drug Monit 2006, 28:793-799.
4. Jalling B. Plasma and cerebrospinal fluid concentrations of phenobarbital in infants given single doses. Dev Med Child Neurol 1974, 11:781-793.
5. Ayrton A., Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001, 31:469-497.
6. de Wildt S.N., Kearns G.L., Hop W.C., et al. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002, 53:390-392.
7. Haig G.M., Bockbrader H.N., Wesche D.L., et al. Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. J Clin Pharmacol 2001, 41:507-514.
8. Cvetkovic M., Leake B., Fromm M.F., et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999, 27:866-871. Kim RB.
9. Krishna R., Krishnaswami S., Kittner B., et al. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: A case study with fexofenadine hydrochloride. Biopharm Drug Dispos 2004, 25:373-387.
10. Alfonso I., Gilman J., Gilman J., et al. Intravenous valproate dosing in neonates. J Child Neurol 2000, 15:827-829. ALA.
11. Kataria B.K., Ved S.A., Nicodemus H.F., et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 1994, 80:104-122.
12. Anderson G.D. Children versus adults: Pharmacokinetic and adverse-effect differences. Epilepsia 2002, 43(suppl 3):53-59.
13. Barnett H.L. Kidney function in young infants. Pediatrics 1950, 5:171-179.
14. Tod M., Lokiec F., Bidault R., et al. Pharmacokinetics of oral acyclovir in neonates and in infants: A population analysis. Antimicrob Agents Chemother 2001, 45:150-157.
15. Inui K.I., Masuda S., Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000, 58:944-958.
16. Wrighton S.A., Stevens J.C. The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol 1992, 22:1-21.
17. Gardiner S.J., Begg E.J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006, 58:521-590.
18. Zhou S.F., Liu J.P., Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009, 41:89-295.
19. Benet L.Z., Hoener B.A. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002, 71:115-121.
20. Anderson G.D. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol 2006, 2:947-960.
21. Papetti L., Spalice A., Nicita F., et al. Migraine treatment in developmental age: guidelines update. J Headache Pain 2010, 11:267-276.
22. Richer L.P., Laycock K., Millar K., et al. Treatment of children with migraine in emergency departments: National Practice Variation Study. Pediatrics 2010, 126:e150-e155.
23. Fuseau E., Petricoul O., Moore K.H., et al. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002, 41:801-811.
24. Miano S., Ferri R. Epidemiology and management of insomnia in children with autistic spectrum disorders. Paediatr Drugs 2010, 12:75-84.
25. Pelayo R., Dubik M. Pediatric sleep pharmacology. Semin Pediatr Neurol 2008, 15:79-90.
26. Krisanaprakornkit T., Ngamjarus C., Witoonchart C., et al. Meditation therapies for attention-deficit/hyperactivitydisorder (ADHD). Cochrane Database Syst Rev 2010, 6. CD006507.
27. Delgado M.R., Hirtz D., Aisen M., et al. Practice parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010, 74:336-343.
28. Nicotra A., Pierucci F., Parvez H., et al. Monoamine oxidase expression during development and aging. Neurotoxicology 2004, 25:155-165.
29. Lewinsohn R., Glover V., Sandler M. Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem Pharmacol 1980, 29:1221-1230.
30. Battino D., Estienne M., Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 1995, 29:341-369.
31. Battino D., Estienne M., Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet 1995, 29:257-286.
32. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006, 45:351-363.
33. Witcher J.W., Long A., Smith B., et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003, 13:53-63.
34. Taketomo C., Hodding J., Kraus D. Pediatric Doage Handbook 2005, Lexi-Comp, Cleveland, OH.
35. Nishina K., Mikawa K., Shiga M., et al. Clonidine in paediatric anaesthesia. Paediatr Anaesth 1999, 9:187-202.
36. Lietman P.S., Haslam R.H., Walcher J.R. Pharmacology of dantrolene sodium in children. Arch Phys Med Rehabil 1974, 55:388-392.
37. Brown G.L., Hunt R.D., Ebert M.H., et al. Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. Psychopharmacology (Berl) 1979, 62:133-140.
38. Mandelli M., Tognoni G., Garattini S. Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 1978, 3:72-91.
39. Simons K.J., Watson W.T., Martin T.J., et al. Diphenhydramine: Pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. J Clin Pharmacol 1990, 30:665-671.
40. Wigal S.B., Gupta S., Greenhill L., et al. Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007, 17:153-164.
41. Marchei E., Farre M., Pardo R., et al. Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. Clin Chem 2010, 56:585-592.
42. Blumer J.L., Reed M.D., Steinberg F., et al. Potential pharmacokinetic basis for zolpidem dosing in children with sleep difficulties. Clin Pharmacol Ther 2008, 83:551-558.